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The enzyme paraoxonase 1 (PON1; EC 
3.1.8.1) detoxifies activated (oxon) organo-
phosphorus pesticides (OPs), which are neuro-
toxic (Costa et al. 2005a; Furlong et al. 2002). 
PON1 also is an antioxidant, and several stud-
ies indicate that it inhibits oxidation of low-
density lipoprotein, a marker of oxidative stress 
(James 2006; Li et al. 2003). PON1 genotypes 
and enzyme activities have been associated with 
numerous health outcomes related to OP expo-
sure and oxidative stress, including Alzheimer’s 
disease (Erlich et al. 2006), Parkinson’s disease 
(Zintzaras and Hadjigeorgiou 2004), cardio-
vascular disease (Bhattacharyya et al. 2008), 
and preterm birth (Chen et al. 2004; Lawlor 
et al. 2006). Studies of in utero OP exposures 
have also demonstrated potential gene–envi-
ronment interactions with PON1. Berkowitz 
et al. (2004) found that among pregnant 
women with measureable levels of chlorpyrifos 
in their blood, those with lower PON1 levels 
had children with smaller infant head circum-
ferences at birth. The same research group also 
reported that higher maternal OP exposure 
(measured by urinary metabolites) was sig-
nificantly associated with decreased child birth 
weight among mothers with the PON1192QQ 
genotype (Wolff et al. 2007). PON1 enzyme 
activities and levels vary broadly in humans 
(Costa et al. 2005b), and the determinants of 
PON1 variation, including genetics and age, 
may further explain the role this enzyme plays 
in relation to exposures and diseases.
Several common polymorphisms in the 
coding and promoter regions of the PON1 
gene influence substrate-specific PON1 
enzyme activities (Brophy et al. 2001; Ferre 
et al. 2003), particularly single-nucleotide 
polymorphisms (SNPs) at positions 192 
and –108 (James et al. 2005). The SNP at 
codon 192 results in an amino acid substitu-
tion from the active-site residue glutamine 
(Q) to arginine (R), and the catalytic effi-
ciency of the PON1192R alloform toward the 
oxon derivatives of OP pesticides parathion 
and chlorpyrifos is greater than that of the 
PON1192Q alloform. Recent studies have 
demonstrated that the PON1192 genotype 
accounts for a large portion of the variation 
of PON1 activity toward the OP substrate 
paraoxon in Caucasian and African-American 
(59%) adults (Bhattacharyya et al. 2008) and 
also in a Mexican-American (48%) popula-
tion (Rainwater et al. 2008). Of the promoter 
polymorphisms, the PON1‑108 SNP exerts 
the most noticeable effect on arylesterase 
(AREase) activity, a measure of PON1 quan-
tity (22.4%), such that the C allele is associ-
ated with increased PON1 levels compared 
with the T allele (Brophy et al. 2001; Deakin 
et al. 2003). Although genetic polymor-
phisms account for a large portion of PON1 
variation, it is not sufficient in epidemiologic 
studies to consider PON1 genotypes alone 
(Jarvik et al. 2000; Richter and Furlong 
1999). Interindividual variability of PON1 
phenotypes can range widely even among 
individuals with the same PON1 genotypes 
because enzyme levels can also be different. 
Therefore, studies that measure PON1 activi-
ties may be more informative than studies 
that rely solely on PON1 genotype data.
Several animal studies have demonstrated 
that low PON1 activity during development 
results in a reduced metabolic cap  acity in 
the young and therefore an increased suscep-
tibility to OP toxicity (Moser et al. 1998; 
Timchalk et al. 2007). Similarly in humans, 
PON1 levels in infants are much lower than 
levels in adults (Chen et al. 2003; Holland 
et al. 2006). Furthermore, preterm babies 
have 24% lower activities compared with 
term babies (Ecobichon and Stephens 1973), 
suggesting that PON1 levels in the fetus 
may be even lower. A few studies have mea-
sured PON1 activities in healthy young chil-
dren at single points in time (Garces et al. 
2008; Karikas et al. 2006; Sumegova et al. 
2007; Vincent-Viry et al. 2003), but only 
one study has described the ontogenetic pro-
file of PON1 activity in the same individu-
als over time. This study (Cole et al. 2003) 
of nine children demonstrated high inter-
individual variation of PON1 from birth to 
2 years of age; PON1 activities increased over 
time and reached a plateau between 6 months 
and 2 years of age in most, but not all, indi-
viduals. PON1 activity is relatively stable in 
adults (Costa et al. 2005b); however, in the 
elderly, it decreases steadily over time (Seres 
et al. 2004). To date, longitudinal changes in 
PON1 activity in children after 2 years of age 
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and potential differences between genotypes 
have not yet been characterized.
Previously, we reported a relatively high 
level of OP exposure in the Salinas Valley, 
California, the location of our longitudinal 
birth cohort (Bradman et al. 2005, 2007). 
Additionally, we observed associations between 
in utero OP exposure and decreases in gesta-
tional duration (Eskenazi et al. 2004), abnormal 
reflexes in neonates (Young et al. 2005), poorer 
mental development at 2 years of age (Eskenazi 
et al. 2008), and increases in maternal report of 
pervasive development disorder (Eskenazi et al. 
2008) in these children. Initially, we reported 
PON1 activity in 130 mothers and their new-
borns and demonstrated much lower activities 
in the newborns (Furlong et al. 2006; Holland 
et al. 2006). In the present study, we measured 
PON1 activity in 458 children at several time 
points spanning birth through 7 years of age to 
determine the ontogeny of PON1 phenotypes. 
In the same children, we also genotyped two 
PON1 SNPs (–108 and 192) known to influ-
ence phenotypic variation and examined how 
PON1 genotypes affect children’s PON1 activi-
ties at different ages.
Materials and Methods
Study subjects. The Center for Health 
Assessment in Mothers and Children of 
Salinas (CHAMACOS) study is a longitudi-
nal birth cohort study of the effects of pesti-
cide and other environmental exposures on 
neurodevelopment, growth, and respiratory 
disease in children from primarily Mexican-
American families (Eskenazi et al. 2003). 
Located in Monterey County, California, the 
Salinas Valley is an area of heavy agricultural 
production where approximately 200,000 kg 
of OPs are applied annually (Department of 
Pesticide Regulation 2005). Women and chil-
dren in this community are at risk for higher 
exposures to pesticides through direct expo-
sure if they live near agricultural fields or if the 
mother works in the field, and through the 
take-home pathway. A total of 601 pregnant 
women were enrolled in the CHAMACOS 
study, and 528 delivered newborns. Mothers 
in the CHAMACOS cohort were primarily 
young (mean ± SD, 25.6 ± 5.3 years), mar-
ried, low-income, Mexican-born, Spanish-
speaking women who were farmworkers 
themselves (44%) or lived with farmworkers 
at the time of enrollment (84%). Ethnicity 
of children and mothers was based on moth-
ers’ self-report. For this particular study, we 
limited analyses to include only subjects who 
were of Mexican descent (97%). More than 
half the women in CHAMACOS came from 
three states in Mexico: Michoacán (23%), 
Guanajuato (21%), and Jalisco (11%). Study 
protocols were approved by the University of 
California–Berkeley human subjects review 
committee. Written informed consent was 
obtained from all mothers, which included 
consent for their children to participate.
Blood collection and processing. Blood spec-
imens were collected from 458 CHAMACOS 
children (50.1% boys) for the measurement of 
PON1 enzyme activity. Umbilical cord blood 
samples (n = 336) were collected by delivery 
room staff once the baby was safely delivered. 
Blood specimens were also collected from chil-
dren at approximately 1 year of age (n = 52; 
mean ± SD, 1.07 ± 0.19 years), 2 years of age 
(n = 249; 2.01 ± 0.09 years), 5 years of age 
(n = 225; 5.10 ± 0.22 years), and 7 years of 
age (n = 281; 7.10 ± 0.23 years). We were able 
to meas  ure PON1 enzyme activity at four or 
more time points for 108 of these children.
Heparinized whole blood was collected 
in BD Vacutainers (Becton, Dickinson and 
Company, Franklin Lakes, NJ), centrifuged, 
and then divided into plasma, buffy coats, 
and red blood cells and stored at –80°C. 
Vacutainers without anticoagulant were used 
to collect serum and clot. DNA was isolated 
from blood clots as described previously 
(Holland et al. 2006).
Determination of PON1 levels and activi-
ties. We measured PON1 enzyme activity 
toward three substrates [paraoxon (PO), phenyl 
acetate (aryl ester; ARE), and chlorpyrifos-oxon 
(CPO)] in plasma samples using spectropho-
tometric methods as described previously 
(Richter and Furlong 1999). The AREase assay 
is considered a measure of PON1 enzyme 
quantity because rates of phenyl acetate hydro-
lysis do not differ between PON1192 Q and 
R alloforms as they do for paraoxon hydro-
lysis (POase). Methods based on ELISA  and 
Western blot using PON1 antibodies confirm 
a high correlation (r > 0.85) between measured 
PON1 quantity and AREase activity (Connelly 
et al. 2008; Kujiraoka et al. 2000). In contrast, 
POase and chlorpyrifos-oxonase (CPOase) 
substrate-specific assays reflect both quantity 
and catalytic efficiency of the enzyme. In this 
article, we refer to enzyme quantity measured 
by AREase activity as PON1 levels. CPOase 
and POase activities (quantity and substrate-
specific efficiency) are referred to as enzyme 
activity. All assays were performed in triplicate. 
Quality assurance, described in more detail 
by Huen et al. (2009), included assessment of 
repeat samples (separate aliquots of the same 
sample run on different days), internal controls 
(aliquots of the same sample run on all assay 
plates), and concurrent analyses of specimens 
from different time points (samples from dif-
ferent time points run on the same plates). 
Repeated analysis of 3% of samples showed 
a high degree of concordance. For the three 
substrate-specific assays, the average coefficient 
of variation (CV) for repeated samples ranged 
from 6% to 9%, and the correlation coeffi-
cients between repeated runs ranged from 0.91 
to 0.98. Interassay variability, as measured by 
the average CV for internal controls samples, 
was between 7 and 9%.
Determination of PON1 genotypes. The 
coding polymorphism, PON1192, was geno-
typed using the TaqMan real-time polymerase 
chain reaction (PCR) method. Briefly, primers 
for the nucleotide sequence flanking the SNP 
and probes specific for the SNP were custom 
designed by Applied Biosystems, Inc. (Foster 
City, CA). The promoter SNP, PON1‑108, 
was genotyped using a fluorogenic allele-spe-
cific genotyping assay (Amplifluor; Flowgen 
Biosciences Ltd., Nottingham, UK). This 
assay required a two-part nested PCR strategy, 
where the region surrounding the SNP was 
preamplified using nonallelic flanking primers. 
The amplicon was then diluted and used as 
the template for the Amplifluor assay. Quality 
assurance procedures for genotyping both 
PON1 SNPs included assessment of randomly 
distributed blank samples in each plate and 
duplicates of randomly selected samples with 
independently isolated DNA from the same 
subjects. Repeated analysis (4% of samples) in 
several runs showed a high degree (> 99%) of 
concordance. All discrepancies were resolved 
with additional genotyping.
Statistical analysis. To model longitudinal 
changes of PON1 enzyme activity, we used 
generalized estimating equations (GEEs) with 
an exchangeable correlation structure because 
we had repeated measures on individual sub-
jects. This method is often advantageous in 
longitudinal models because inferences based 
on robust estimators are less dependent on 
the assumption that the data are normally dis-
tributed (Hox 2002). Correlations of mea-
surements on individuals at various ages were 
similar. We created separate models for each 
of the three outcomes, AREase, CPOase, and 
POase activity. Independent variables in the 
model included age (years), PON1 genotype 
(either PON1192 or PON1‑108), and an inter-
action term between age and PON1 genotype 
(age × PON1192 or age × PON1‑108). Because 
the number of specimens collected at 1 year 
of age was much smaller than at other time 
points, we also ran GEE models without this 
time point. However, because results did not 
change significantly, we show only the GEE 
models using all time points.
We previously established that storage 
duration can affect PON1 activity, particu-
larly in specimens that had been stored for 
> 2 years (Huen et al. 2009). PON1 activ-
ity decreased on average by 17.1%, 39.4%, 
and 37.6% for AREase, CPOase, and POase, 
respectively after 5 years of storage (p < 0.001 
for all three assays). This decline of PON1 
enzymatic activity over time has also been 
reported in other studies (Brackley et al. 1983; 
Stenzel et al. 2007). In this study, specimens 
collected at earlier ages were sometimes stored 
for > 2 years, so age and storage duration were Huen et al.
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inversely correlated with each other (Pearson’s 
correlation coefficient r = 0.986). To estimate 
the effects of age while taking into account the 
potential effects of storage duration, we gener-
ated a storage duration correction factor using 
pilot data from a previous study (Huen et al. 
2009). Briefly, parallel aliquots of specimens 
from 95 subjects were assayed after 2 years and 
7 years of storage at –80°C. Measured AREase, 
CPOase, and POase activities were signifi-
cantly lower after 7 years of storage compared 
with 2 years of storage. Using these data, we 
constructed linear models to predict the per-
cent change in PON1 activity as a function of 
years of storage duration and storage duration 
× assay temperature. The models including an 
interaction between storage duration and assay 
temperature had the lowest Akaike Information 
Criterion and were thus selected to be used to 
determine the correction factors. The intercept 
was constrained to equal zero. We then used 
the resultant coefficients from these models as 
correction factors to predict the PON1 activity 
(AREase, CPOase, POase) at a storage time of 
zero years, and used the storage duration–cor-
rected PON1 activity measures in subsequent 
GEE models to determine the effects of age on 
PON1 activity as described above.
Because we could not completely eliminate 
the residual confounding by storage duration 
in our GEE models, we conducted additional 
analyses to provide evidence that the associa-
tion between age and PON1 substrate-specific 
measures is not attributable solely to the strong 
correlation of age with storage duration. We 
performed a likelihood ratio test comparing 
a full model, including terms for age, storage, 
PON1 genotype, and the interaction between 
age and genotype, with a restricted model 
without the age terms. It indicated that age 
should be retained in the model and that the 
fit of the full model was significantly better 
(p < 0.0001). Additionally, because the cor-
relation between age and storage duration was 
considerably weaker within shorter time inter-
vals (r = –0.3 between 1- and 2-year-olds and 
r = –0.93 between 5- and 7-year-olds), we also 
ran GEE models including a term for duration 
of storage in data sets restricted a) only to 1- 
and 2-year-olds and b) only to 5- and 7-year-
olds. In the models for 1- and 2-year-olds, an 
interaction term for PON1 genotype and age 
was not included because there was not suffi-
cient power with the limited sample size.
All analyses were performed in STATA 
(version 10.0; StataCorp, College Station, 
TX) and R (version 2.7.0; R Development 
Core Team 2008).
Results
PON1 polymorphisms. Genotype distributions 
did not deviate significantly from Hardy–
Weinberg equilibrium. For the PON1192 poly-
morphism, the allele frequencies of the Q and 
R alleles were 50.2% and 49.8%, respectively, 
and genotype frequencies were 23.2%, 53.1%, 
and 23.7% for QQ, QR, and RR genotypes 
(Table 1), respectively. Genotype frequencies 
for PON1‑108 were 28.3%, 53.3%, and 18.4% 
for CC, CT, and TT, respectively. The allele 
frequency of the major allele C was 54.7%.
Effect of age on enzyme activity. Table 2 
lists descriptive statistics for AREase, CPOase, 
and POase activity at birth and 1, 2, 5, and 7 
years of age. Mean PON1 enzyme activity in 
CHAMACOS children was lowest in new-
borns for all three substrate-specific assays and 
highest at 7 years of age, and there were no 
differences in PON1 activity by sex (analysis 
of variance, F < 1.14; p > 0.30 for all three 
PON1 assays at all time points). Mean ± SD 
AREase activity, which is considered a meas-
ure of PON1 levels (quantity), approximately 
doubled from 33.1 ± 14.5 U/mL at birth 
to 66.5 ± 30.4 U/mL at 1 year of age and 
quadrupled (compared with birth) to 121.5 
± 30.3 U/mL at 7 years of age. Although 
PON1 activity did not increase appreciably 
between 2 and 5 years of age for AREase and 
CPOase, all three substrate specific measures 
grew noticeably between 5 and 7 years of age. 
At birth, differences in overall enzymatic activ-
ity between newborns with the lowest and 
highest values were 26-, 34-, and 136-fold for 
AREase, CPOase, and POase, respectively. In 
7-year-old children, the fold differences were 
somewhat smaller (17-, 13-, and 21-fold for 
AREase, CPOase, and POase, respectively).
Effects of PON1 genotype on enzyme activ-
ity. Within each age group, the PON1 enzyme 
levels were influenced by both PON1192 and 
PON1‑108. Mean AREase values differed by the 
PON1192 polymorphism (p for trend < 0.05 
for increasing number of R alleles). At birth, 
average AREase levels were 15.8% higher in RR 
children than QQ children (Table 1). In con-
trast, at 2, 5, and 7 years of age, mean AREase 
activity was 9.8–14.1% higher in QQ children 
than in RR children. Mean AREase activity also 
varied by PON1‑108 genotypes, and these differ-
ences were larger at all ages than for PON1192. 
At birth, mean AREase activity was 18.9 U/mL 
or about 44.9% lower in TT newborns than in 
CC newborns (Figure 1D). PON1 levels con-
tinued to be lower in CC children (p for trend 
< 0.001 for all time points except at year 1), 
with differences ranging from 18.8% to 25.4% 
in 2-, 5-, and 7-year-old children.
The PON1192 SNP explained a relatively 
small amount of the variance of AREase 
Table 1. PON1 polymorphisms and AREase (U/mL) enzyme activity in children of various age groups.
Frequencya 
 (%)
Birth (n = 336) 1 year (n = 52)  2 years (n = 249) 5 years (n = 225) 7 years (n = 281) Mothersb (n = 130)
Mean ± SD Range Mean ± SD Range Mean ± SD Range Mean ± SD Range Mean ± SD Range Mean ± SD Range
192
  QQ 23.2 31.7 ± 15.5* 3.9–70.9 77.5 ± 22.7 52.2–126.6 93.0 ± 25.2* 16.4–143.3 92.3 ± 26.9* 36.5–157.9 129.5 ± 36.3 52.9–246.3 151.9 ± 46.8 19.8–237.5
  QR 53.1 32.2 ± 14.4 3.8–98.0 65.6 ± 29.6 7.3–125.4 84.8 ± 25.8 8.5–151.2 81.5 ± 20.5 22.4–131.3 119.8 ± 29.1 14.5–184.6 144.3 ± 44.6 72.9–261.9
  RR 23.7 36.7 ± 13.0 9.7–73.6 59.5 ± 36.3 5.9–103.5 84.7 ± 23.0 17.7–136.9 80.9 ± 18.6 22.9–111.3 117.6 ± 25.3 61.1–190.4 152.2 ± 48.6 78.9–281.4
–108
  CC 28.3 42.1 ± 13.0** 13.9–90.3 73.8 ± 34.9 5.9–125.4 98.2 ± 27.7** 13.9–151.2 95.8 ± 23.8** 42.0–157.9 138.5 ± 30.3** 73.3–246.3 163.6 ± 51.0* 78.9–281.4
  CT 53.3 32.0 ± 13.5 3.8–98.0 64.8 ± 29.5 7.3–126.6 83.7 ± 22.8 8.5–143.3 81.3 ± 19.4 22.9–144.0 120.6 ± 27.6 14.5–198.9 147.1 ± 43.3 19.8–242.8
  TT 18.4 23.2 ± 11.1 3.9–54.7 59.0 ± 27.6 10.0–99.3 79.7 ± 21.8 26.7–137.6 73.9 ± 20.4 22.4–109.8 103.3 ± 23.7 33.6–159.9 134.8 ± 43.3 54.5–233.7
aGenotype frequency was reported for children with enzyme activity measured at birth. Other time points had similar frequencies. bMeasurements of PON1 enzymatic activity were 
taken in pregnant mothers at 26 weeks’ gestation as described previously (Holland et al. 2006). *p < 0.05, **p < 0.001, determined by Cuzick’s test for trend.
Table 2. Summary of PON1 enzymatic activity in children and mothers.
AREase (U/mL) CPOase (U/L) POase (U/L)
Age (years) No. Mean ± SD Range Mean ± SD Range Mean ± SD Range
0 336 33.1 ± 14.5 3.8–98.0 2020.2 ± 860.7 153.9–5255.2 257.1 ± 162.4 7.5–1017.5
1 52 66.5 ± 30.4 5.8–126.6 3995.1 ± 1885.7 195.2–7667.0 570.0 ± 417.1 37.3–1502.7
2 249 87.0 ± 25.1 8.5–151.2 5310.3 ± 1549.9 408.7–9474.5 667.3 ± 390.5 37.5–1813.1
5 225 84.0 ± 22.3 22.4–157.9 5502.4 ± 1424.1 1433.0–9808.1 732.0 ± 417.1 97.6–1855.6
7 281 121.5 ± 30.3 14.5–246.3 7035.8 ± 1700.6 904.2–11576.7 894.2 ± 477.0 119.5–2504.5
Mothersa 130 149.2 ± 46.1 19.8–281.4 9358.3 ± 2794.4 1661.7–17098.0 1024.2 ± 656.4 66.1–3014.2
aMeasurements of PON1 enzymatic activity were taken in pregnant mothers at 26 weeks’ gestation as described previously (Holland et al. 2006).PON1 enzyme activity in young children
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 10 | October 2009  1635
activity at different ages (1.4–3.6%), whereas 
the promoter polymorphism PON1‑108 
accounted for 8.2–24.4% of AREase activity 
[see Supplemental Material, Table 1 (avail-
able online at doi:10.1289/ehp.0900870.S1 
via http://dx.doi.org)]. Although 4.4% of the 
variance of CPOase activity was explained by 
the PON1192 SNP at birth, the coding region 
SNP made a seemingly smaller contribution at 
other time points (0.1–1.2%), and the role of 
PON1‑108 seemed much larger (4.1–27.3%). 
Both SNPs accounted for a significant portion 
of POase activity variation. The contribution 
of PON1192, which was 39.8% at birth, was 
generally higher in older children and highest 
at 7 years of age (70.7%).
Effects of age and PON1 genotype on 
enzyme activity. We used GEE augmentation 
of linear models to determine the effects of 
age and genotype on PON1 activity in chil-
dren (Table 3). Point estimates in the models 
using storage duration–corrected data were 
not markedly different from those generated 
using raw data, although 95% confidence 
intervals (CIs) were slightly wider in storage 
duration–corrected models. Because the results 
for both models were similar, only results 
from the storage duration–corrected models 
are shown. Regression lines were generated 
for AREase, CPOase, and POase activity by 
age and are plotted with respect to PON1192 
(Figure 1A–C) and PON1‑108 (Figure 1D–F) 
genotypes. All three substrate-specific PON1 
enzyme activities were positively associated with 
age (p < 0.0001 for all models). It appeared 
that PON1 activities continued to increase past 
the age of five because paired t-tests showed 
that AREase, CPOase, and POase were all sig-
nificantly higher in 7-year-olds than in 5-year-
olds (p < 0.0005).
For AREase activity, there was a small but 
statistically significant interaction (p = 0.016) 
between age and PON1192 genotype in which 
the slopes for age were lowest (8.3 U/mL per 
year) for RR children and highest (10.3 U/
mL per year) for QQ children (Figure 1A). 
The promoter polymorphism, PON1‑108, had 
a more pronounced effect on AREase activity 
than did PON1192. Furthermore, we observed 
a small but significant interaction (p = 0.027) 
between age and PON1‑108 genotype in which 
mean AREase activity increased 10.0, 9.1, and 
8.2 U/mL per year increase in age for CC, 
CT, and TT children, respectively.
Similar to AREase, CPOase activity was 
modestly associated (p = 0.017) with PON1192 
genotype (Table 4, Figure 1B). Mean CPOase 
activity was 591.0 U/mL (95% CI, 104.6–
1,077.4 U/mL) higher in RR children and 
295.5 U/mL (95% CI, 52.3–538.7 U/mL) 
higher in QR children than in QQ children. 
There was no interaction between age and 
PON1192 genotype. In contrast, we did observe 
a small but significant interaction between age 
and PON1‑108 genotype (β-estimate for age × 
PON1‑108 genotype = –54.6, p = 0.022).
We also observed significant effect modifi-
cation by the PON1192 genotype (p < 0.0001) 
on the relationship between age and POase 
activity (Figure 1C). POase activity increased 
with age for all PON1192 genotypes, but the 
slopes for age were much steeper for RR chil-
dren. For example, mean activity increased 
by only 21.8 U/L (95% CI, 15.3–28.3 U/L) 
per year in QQ children, whereas in RR 
children mean activity increased 119.2 U/L 
or almost 5.5-fold more per year (95% CI, 
97.7–140.9 U/L). The effect is so large that 
even at 7 years of age the average POase activ-
ity in QQ children was lower than the average 
POase activity in QR and RR   children at 
2 years of age. Although not as strikingly 
as the coding polymorphism PON1192, the 
promoter SNP, PON1‑108, also influenced 
POase activity significantly (Figure 1F). The 
effect of age on POase activity was modified 
by PON1‑108 genotype (p < 0.0001) such that 
slopes for mean POase activity per year were 
highest in CC children and lowest in TT 
  children.
To determine the effects of combinations 
of PON1192 and PON1‑108 genotypes on 
enzyme activity, we performed GEE models 
comparing children with the PON1‑108CC192RR 
homozygous diplotype (reference group) with 
those with the PON1‑108TT192QQ homozygous 
Figure 1. PON1 enzyme activity by age (years) and PON1 genotype. (A–C) AREase (A), CPOase (B), and 
POase (C) activity (corrected for storage duration) plotted by age for QQ (red), QR (blue), and RR (green) 
PON1192 genotypes. (D–F) PON1 enzyme activities plotted by age for CC (green), CT (blue), and TT (red) 
PON1-108 genotypes. The overlaid regression lines are the predicted values generated by GEE models on 
the storage duration–corrected data as shown in Table 4. For all three substrate-specific assays, PON1 
activity increased with age (p < 0.0001). The effect of age on POase activity significantly differed by geno-
type, as illustrated by the steeper slopes for RR (119.2 U/L per year; 95% CI, 97.7–140.9) children compared 
with QQ (21.8 U/L per year; 95% CI, 15.3–28.3) children (C). The C-108T genotype was significantly associ-
ated with all three assays (D–F). CC children had the highest mean activities, whereas TT children had the 
lowest mean activities. For POase activity, the slopes for CC children were steeper than slopes for CT and 
TT children (F), demonstrating the significant interaction between age and C-108T genotype (p < 0.0001).
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diplotype (Table 4). Children with the PON1‑
108TT192QQ diplotype had significantly lower 
mean AREase (14.1 U/mL; 95% CI, 3.7–
24.4 U/mL), CPOase (1525.9 U/L; 95% 
CI, 835.0–2216.3 U/L), and POase (627.4 
U/L; 95% CI, 534.5–720.4 U/L) activities 
compared with PON1‑108CC192RR children. 
Additionally, we observed a statistically sig-
nificant interaction between age and diplo-
type on POase activity (p < 0.0001). The 
slope for mean POase activity over age was 
much steeper for PON1‑108CC192RR children 
(135.3 U/L per year; 95% CI, 115.0–155.7 
U/L) than for PON1‑108TT192QQ children, 
which was 112.6 U/L per year (95% CI, 91.3–
133.8 U/L) lower.
Effects of age and PON1 genotype on 
enzyme activity in restricted data sets. Because 
the correlation between age and storage dura-
tion was appreciably smaller within shorter 
time intervals, we were able to include a stor-
age duration term (rather than use the stor-
age duration–corrected data) in GEE models 
where the time interval was restricted to a) 
1- and 2-year-olds only or b) 5- and 7-year-
olds only. The results are presented in Table 
4. For 1- and 2-year-olds, age was signifi-
cantly associated with all three substrate-spe-
cific measures of PON1 even after adjusting 
for potential cofounding by storage duration 
(p < 0.001 for AREase and CPOase and p = 
0.016 for POase). Further, storage duration 
was only significantly associated with POase 
activity (p = 0.04), and the magnitude of the 
effect (–55.8 U/L) was much smaller than 
the effect of age (128.0 U/L). Similarly, for 
5- and 7-year-olds, age was strongly associ-
ated with AREase, CPOase, and POase (p 
< 0.001) activities, and storage duration was 
not. For POase, the prominent interaction 
between age and PON1192 genotype observed 
in the storage duration–corrected models was 
also significant in these models (p = 0.02).
Correlation analysis. Correlations of each 
of the PON1 substrate-specific enzyme activi-
ties in children at different time points were 
highly significant except at 1 year of age, when 
there was a weak correlation with 7-year-olds 
and no correlation with cord blood samples 
at birth. This may be attributable to the rela-
tively small sample size at 1 year of age. Further, 
because the cord blood measurement accounts 
for both fetal and placental expression, the cor-
relation between these two time points (birth 
and 1 year of age) may be weaker than with 
other age groups. For pairwise comparisons 
among all other age groups (birth and 2, 5, 
and 7 years of age), Pearson’s correlation coef-
ficients ranged from 0.37 to 0.62 for AREase 
and from 0.41 to 0.73 for CPOase assays. 
POase measurements were even more highly 
correlated, with correlation coefficients ranging 
from 0.70 to 0.93 [see Supplemental Material, 
Table 2 (available online at doi:10.1289/
ehp.0900870.S1)]. Within each time point, 
all three PON1 activities were also signifi-
cantly correlated with each other (p < 0.001). 
The correlation coefficients tended to be high-
est between CPOase and AREase, ranging 
from 0.84 to 0.97. The pairwise correlation 
coefficients between POase and CPOase 
ranged from 0.44 to 0.78. Between POase 
and AREase, the correlation coefficients 
were lower, ranging from 0.23 to 0.65 [see 
Supplemental Material, Table 3 (available 
online at doi:10.1289/ehp.0900870.S1)].
Discussion
In this study, we examined the ontogeny of 
PON1 phenotypes in a longitudinal birth 
cohort of 458 children who were followed from 
birth through 7 years of age. Our data demon-
strated a dramatic range of PON1 variability in 
young children, particularly in newborns. We 
observed an age-dependent increase in measures 
of PON1 levels and enzymatic activity that 
continued through 7 years of age. Furthermore, 
for POase activity, the rates of increase were 
allele specific, such that children with PON1192R 
alleles experienced a much more pronounced 
increase in POase activity over time. Similarly, 
children with the PON1‑108CC192RR diplotype 
had significantly higher mean PON1 activities 
and also experienced steeper increases of POase 
activity over time compared with children with 
the PON1‑108TT192QQ diplotype.
Earlier studies (Chen et al. 2003; Holland 
et al. 2006 ) demonstrated that newborns have 
lower PON1 levels than adults. Cole et al. 
(2003) reported that PON1 levels (AREase) 
and activities (POase) increased noticeably in 
nine children during the first year of life and 
appeared to have plateaued by 2 years of age 
in some but not all of them. In contrast, our 
study, which followed a much larger number 
of children for a longer period of time, demon-
strated that children’s PON1 levels and activi-
ties continue to increase past 2 years of age 
until at least 7 years of age. These data suggest 
that children’s PON1 activities remain lower 
than their expected adult levels longer than pre-
viously thought. Although this phenomenon 
has not yet been reported in other epidemio-
logic studies, similar observations in mice have 
also shown that PON1 levels are low at birth 
and increase significantly with age (Zemke 
et al. 2009). Because PON1 can detoxify acti-
vated OPs and also has antioxidant properties, 
our findings provide evidence that the time in 
which infants and young children remain more 
vulnerable than adults to OP exposures and 
oxidative stress may extend from birth through 
7 years of age and possibly even later.
In addition to the age-dependent increases 
in PON1 measures, our data in this large 
Mexican-American cohort corroborate allele 
and genotype frequencies of the PON1 SNPs 
at positions –108 and 192 in other studies of 
Mexican and Mexican-American populations 
Table 3. Regression analysis (GEE) of the effects of age and PON1 genotype on PON1 enzyme activity (storage duration–corrected data).
Q-192Ra C-108Tb Q-192R and C-108T homozygous diplotypesc
β-Estimate 95% CI p-Value β-Estimate 95% CI p-Value β-Estimate 95% CI p-Value
AREase
  Intercept 55.3 50.8 to 59.8 < 0.0001 64.8 61.0 to 68.7 < 0.0001 64.5 58.6 to 70.3 < 0.0001
  Aged 10.3 9.2 to 11.4 < 0.0001 10.0 9.1 to 11.0 < 0.0001 9.0 7.8 to 10.3 < 0.0001
  Genotype 0.3 –3.3 to 3.8 0.884 –9.9 –13.3 to –6.4 < 0.0001 –14.1 –24.4 to –3.7 0.008
  Age × genotypee –1.0 –1.9 to –0.2 0.016 –0.9 –1.7 to –0.1 0.027 0.04 –0.1 to 0.2 0.648
CPOase
  Intercept 3728.1 3431.1 to 4025.1 < 0.0001 4765.6 4495.1 to 5036.1 < 0.0001 4801.0 4376.7 to 5225.4 < 0.0001
  Age 486.7 422.8 to 550.6 < 0.0001 515.5 460.0 to 570.9 < 0.0001 516.2 432.7 to 599.8 < 0.0001
  Genotype 295.5 52.3 to 538.7 0.017 –800.1 –1033.7 to –566.5 < 0.0001 –1525.9 –2216.3 to –835.6 < 0.0001
  Age × genotype –17.5 –68.3 to 33.3 0.500 –54.6 –101.3 to –8.0 0.022 –42.8 –175.2 to 89.7 0.527
POase
  Intercept 173.0 144.1 to 202.0 < 0.0001 547.1 499.2 to 595.1 < 0.0001 759.8 672.1 to 847.6 < 0.0001
  Age 21.8 15.3 to 28.3 < 0.0001 94.7 81.0 to 108.5 < 0.0001 135.3 115.0 to 155.7 < 0.0001
  Genotype 258.2 224.5 to 291.8 < 0.0001 –127.3 –164.6 to –89.9 < 0.0001 –627.4 –720.4 to –534.5 < 0.0001
  Age × genotype 48.7 41.2 to 56.3 < 0.0001 –27.1 –37.8 to –16.5 < 0.0001 –112.6 –133.8 to –91.3 < 0.0001
aPON1192 was coded 0, 1, and 2 for QQ, QR, and RR genotypes, respectively. The total number of children included in this model was 443. bPON1-108 was coded 0, 1, and 2 for CC, CT, and 
TT genotypes, respectively. The total number of children included in this model was 439. cIndividuals with the PON1192RR and PON1-108CC diplotype were coded 0, and individuals with 
the PON1192QQ and PON1-108TT diplotype were coded 1. The number of children included in this model was 84. dAge was expressed in years. eAge × genotype refers to the interaction 
term between age and genotype (PON1192, PON1-108, or PON1192–108 diplotype). PON1 enzyme activity in young children
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(Rainwater et al. 2008; Rojas-Garcia et al. 
2005). Consistent with other studies, we 
found that the Q allele of the PON1192 coding 
polymorphism was associated with decreased 
POase activities and that the C allele of the 
PON1‑108 promoter polymorphism was associ-
ated with increased activity in all three PON1 
measures (Deakin and James 2004; Furlong 
et al. 2005). In transgenic mouse models, the 
PON1192Q alloform does not protect against 
CPO exposure as well as the PON1192R allo-
form (Cole et al. 2005). Furthermore, mice 
with lower PON1 levels were more sensitive 
to OP toxicity as measured by cholinesterase 
inhibition in the brain (Li et al. 2000). These 
studies demonstrated that because of their 
influence on PON1 levels and catalytic effi-
ciency, the PON1‑108 and PON1192 genotypes 
are significant determinants of sensitivity to 
OP exposure. Furlong et al. (2006) used these 
data to estimate that the range of sensitivity 
to CPO in CHAMACOS mothers and their 
newborns is very wide (131- to 164-fold). 
Although age and PON1 genotype appear to 
affect this variability significantly, it is likely 
that other factors such as environmental expo-
sures and additional genetic polymorphisms 
may account for some of this variability.
To our knowledge, no other studies have 
examined the effects of common polymor-
phisms on the ontogeny of PON1 phenotypes 
in young children. In our study, children with 
the PON1192R and PON1‑108C alleles experi-
enced much steeper increases in POase activity 
with age in a dose-dependent manner (dose of 
allele), indicating significant effect modifica-
tion by PON1192 and PON1‑108 genotypes. A 
similar pattern was reported by Parker-Katiraee 
et al. (2008), who found that PON1 expression 
in murine liver tissue increased during embry-
onic development in an allele-specific manner. 
These data suggest that PON1 ontogeny is 
influenced by genetic polymorphisms and chil-
dren with certain genotypes (PON1192Q and 
PON1‑108T alleles) may be more susceptible to 
the adverse effects of OP exposure and oxida-
tive stress throughout childhood. In addition 
to PON1 genotypes, PON1 developmental 
expression may also be affected by prenatal 
exposure to OPs via epigenetic mechanisms. 
It will be interesting to determine whether 
OP exposure may be associated with PON1 
  ontogeny in future studies.
In our analyses, we performed GEE mod-
els using raw data and also using data cor-
rected for storage duration. Previous studies, 
including our own, have reported a decline 
in POase, AREase, and diazoxonase activities 
over time, particularly in samples stored for 
several years (Brackley et al. 1983; Huen et al. 
2009; Stenzel et al. 2007). To adjust for stor-
age duration, we created a correction factor 
by constructing linear models from a data set 
of 95 subjects whose PON1 activities were 
measured at two time points. Although it is 
possible that the relationship between stor-
age duration and PON1 activity may not be 
linear, it was the most reasonable assumption 
to use with only two time points available. 
This assumption would tend to overestimate 
the effect of storage duration, thus biasing 
the effect of age on PON1 activity toward 
the null. We also assumed that variance in 
measurements at the two time points was due 
primarily to storage duration and not other 
unmeasured factors. Although the storage 
duration–corrected data introduces a degree of 
uncertainty into our models, we were still able 
to identify highly significant age-dependent 
increases in all three PON1 measures using 
this data. In addition to the models using stor-
age duration data, we were able to apply GEE 
models to subsets of the data (smaller time 
intervals) in which the correlation between 
age and storage duration was weaker. In these 
models, where a term for storage duration was 
included, we confirmed our findings that age is 
positively associated with PON1 activity after 
adjustment for storage duration. Despite the 
potential limitations of our analysis, this is the 
largest longitudinal study examining PON1 
activity during childhood development. Use of 
a cross-sectional study design in future studies 
may help to confirm our results while avoiding 
the potential bias introduced by storage dura-
tion effects on PON1 activity.
From our data, it is not yet apparent when 
children’s PON1 levels and activities reach 
mature levels. Furthermore, levels did not 
increase appreciably between 2 and 5 years of 
age, but then continued to increase between 
5 and 7 years of age. It is possible that the 
approach to puberty may affect levels of this 
physiologically important enzyme. Compared 
with younger children, average PON1 levels 
and activities in 7-year-olds were much closer 
to those we previously reported in pregnant 
CHAMACOS mothers (Holland et al. 2006). 
Whether children with different genotypes 
reach mature levels at different ages remains 
unclear. Because this study was performed in 
a cohort of Mexican-American children with 
relatively high levels of OP exposure, gen-
eralization of the age-dependent increase of 
PON1 activity to other populations should be 
done with caution. Future studies of PON1 
ontogeny should include children as they 
grow older (past 7 years of age) and also addi-
tional populations.
Our present study provides additional evi-
dence that children with the PON1192QQ and 
PON1‑108TT genotypes may represent vulner-
able populations. This may be of particular 
Table 4. Regression analyses of age, genotype, and storage on PON1 enzyme activity in smaller age intervals.
1 vs. 2 years of agea 5 vs. 7 years of ageb 5 vs. 7 years of age, interaction model
β-Estimate 95% CI p-Value β-Estimate 95% CI p-Value β-Estimate 95% CI p-Value
AREase
  Intercept 42.3 4.7 to 79.9 0.027 21.5 –28.1 to 71.0 0.396 23.2 –30.1 to 76.5 0.39
  Agec 21.0 11.8 to 30.2 < 0.001 14.9 8.2 to 21.6 < 0.001 14.6 7.1 to 22.1 < 0.001
  PON1192
d –4.8 –8.8 to –0.7 0.022 –5.3 –9.0 to –1.7 0.004 –7.3 –27.9 to 13.2 0.48
  Storage duratione 1.4 –4.4 to 7.1 0.643 –3.9 –12.8 to 4.9 0.384 –3.9 –12.7 to 5.0 0.39
  Age × PON1192
f 0.3 –3.1 to 3.7 0.85
CPOase
  Intercept 3197.9 879.9 to 5515.9 0.007 1837.6 –985.3 to 4660.5 0.202 2356.9 –636.1 to 5349.9 0.12
  Age 1288.9 712.0 to 1865.9 < 0.001 703.0 318.5 to 1087.5 < 0.001 617.4 197.9 to 1,036.9 < 0.001
  PON1192 190.0 –58.2 to 438.3 0.133 188.5 –13.6 to 390.5 0.068 –412.0 –1644.7 to 820.7 0.51
  Storage duration –139.5 –492.2 to 213.3 0.438 –29.4 –542.0 to 483.2 0.911 –17.4 –530.5 to 495.8 0.95
  Age × PON1192 96.7 –100.4 to 293.8 0.34
POase
  Intercept 280.1 –80.4 to 640.6 0.128 –133.3 –528.7 to 262.0 0.509 76.1 –333.2 to 485.4 0.72
  Age 128.0 23.6 to 232.3 0.016 67.1 13.8 to 120.5 0.014 32.6 –23.2 to 88.4 0.25
  PON1192 412.9 366.6 to 459.2 < 0.001 535.3 501.6 to 568.9 < 0.001 293.1 86.4 to 499.8 0.01
  Storage duration –55.8 –109.0 to –2.6 0.04 6.8 –65.3 to 79.0 0.853 11.7 –59.9 to 83.2 0.75
  Age × PON1192 39.0 6.7 to 71.3 0.02
aThis model included 52 children 1 year of age and 249 children 2 years of age. Of these children, 35 had measurements at both time points. bThis model included 225 children 5 years 
of age and 281 children 7 years of age. Of these children, 189 had measurements at both time points. cAge was expressed in years. dPON1192 was coded 0, 1, and 2 for QQ, QR, and RR 
genotypes, respectively. eStorage duration was expressed in years. fAge × PON1192 refers to the interaction term between age and PON1192 genotype.Huen et al.
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concern in the Mexican-American population, 
including our CHAMACOS subjects, because 
both genotypes are relatively common (23.2% 
QQ, 18.4% TT, and 7.5% QQ and TT). The 
PON1192Q and PON1‑108T alleles are also quite 
frequent in Caucasian populations (73% Q, 
62% T) but much less so in African-American 
populations (27% Q, 15% T) (Chen et al. 
2003). Thus, sensitivity to OP toxicity and oxi-
dative stress may vary between populations.
In summary, we followed a cohort of 
Mexican-American children from a farm-
worker community from birth through 7 years 
of age and found that PON1 levels and activi-
ties continue to increase past 2 years of age and 
possibly even past 7 years of age. Additionally, 
PON1 polymorphisms modify the effect of age 
on enzyme activity such that some children 
experience much steeper increases over time 
than others. These findings suggest that chil-
dren’s PON1 activities continue to increase 
until much later than previously believed, and 
therefore, the window of increased suscep-
tibility to OP exposures and oxidative stress 
may also last much longer in young children. 
Future policies regarding protection from pes-
ticide exposures should take into account that 
children may be particularly vulnerable to OP 
exposures and those with certain PON1 geno-
types may be at even greater risk because of 
lower PON1 levels and activities.
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